Publications
5358 Results
- Journal / Conference
- Journal of Clinical Oncology 10;41(2):336-342
- Year
- 2023
- Research Committee(s)
- Lymphoma
- PMID
- PMID35787017
- PMC
- PMID35787017
- Study Number(s)
- S0016, S0801
Relevance of bone marrow biopsies for response assessment in U.S. National Cancer Institute National Clinical Trials Network follicular lymphoma clinical trials
- Journal / Conference
- Journal of Clinical Oncology Jan 20;41(3):472-478
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36067452
- PMC
- PMC9870237
- Study Number(s)
- CTSU/C80405
Acquired Genomic Alterations on First Line Chemotherapy with Cetuximab/Bevacizumab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of CALGB/SWOG-80405 Trial
- Journal / Conference
- Annals Surgical Oncology Feb;30(2):1099-1109
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36305992
- PMC
- PMC9807536
Phase III Prospectively Randomized Trial of Perioperative 5-FU after Curative Resection, Followed by 5-FU/Leucovorin for Patients with Colon Cancer- Intergroup: A trial of the ECOG-ACRIN Research Group (E1292)
- Journal / Conference
- Journal of Clinical Oncology Jan 20;41(3):590-598
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID36228177
- PMC
- PMC9870230
- Study Number(s)
- S1415CD
A Pragmatic Cluster-Randomized Trial of a Standing Physician Order Entry Intervention for Colony Stimulating Factor use among Patients at Intermediate Risk for Febrile Neutropenia (TrACER) (SWOG S1415)
- Journal / Conference
- Blood Advances Jan 24;7(2):196-204
- Year
- 2023
- Research Committee(s)
- Leukemia
- PMID
- PMID36269846
- PMC
- PMC9841239
- Study Number(s)
- C10403
The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study
- Journal / Conference
- Journal of Clinical Oncology Jan 10;41(2):186-197
- Year
- 2023
- Research Committee(s)
- Melanoma
- PMID
- PMID36166727
- PMC
- PMC9839305
- Study Number(s)
- CTSU/EA6134
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
- Journal / Conference
- JAMA Oncology Feb 1;9(2):251-260
- Year
- 2023
- Research Committee(s)
- Melanoma
- PMID
- PMID36416836
- PMC
- PMC9685550
- Study Number(s)
- S1404
Adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose interferon or ipilimumab in patients with resected melanoma; SWOG S1404, A Randomized Clinical Trial
- Journal / Conference
- Journal of Clinical Oncology Feb 10;41(5):1079-1091
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36367997
- PMC
- PMC9928634
- Study Number(s)
- CTSU/C80702
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy from Adjuvant Therapy in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
- Journal / Conference
- Leukemia and Lymphoma Jan;64(1):250-252
- Year
- 2023
- Research Committee(s)
- Leukemia and Symptom Control and Quality of Life
- PMID
- PMID36226777
- Study Number(s)
- S0432, S0702, S1612
Early Mortality Risk with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1,336 Patients from MRC/NCRI and SWOG
- Journal / Conference
- Journal of Clinical Oncology Jan 10;41(2):243-254
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35944235
- PMC
- PMC9839249
- Study Number(s)
- CTSU/C80702